Clinical trial NCT00986882: To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients
Official title: A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Postoperative Pain
Keywords: Postoperative pain
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2009-09-30
Enrollment: 183
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will assess the analgesic efficacy and safety and tolerability of a single oral dose of SAF312 in postoperative dental pain patients after 3rd molar extraction.


Eligibility criteria: Inclusion Criteria:

* Extraction of two or more impacted (partial or full) third molars. At least one of the impaction should be lower jaw.
* Each patient will evaluate her/his post-surgical pain intensity prior to taking trial medication.
* To be eligible for this trial, post surgical pain must be moderate to severe -- Subjects should be in good health otherwise as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at screening.
* Female subjects should be either postmenopausal or should have had surgical sterilization.

Exclusion Criteria:

* Patients with known hypersensitivity to diclofenac, aspirin, acetaminophen or to antipyretics or with allergies manifested by attacks of asthma, urticaria or acute rhinitis following treatment with aspirin or other agents with cyclooxygenase-inhibiting activity such as NSAIDs.
* Use of antipyretic/analgesic drugs from 48 hrs pre-dose to 24 hrs postdose
* Presence of bleeding disorder (history of excessive bleeding after dental procedures or minor injuries)
* Patients with Diabetes mellitus.
* Presence, history of, or family history of malignant hyperthermia or anesthesia-related events that may be suggestive of malignant hyperthermia.
* An abnormal ECG at screening, including PR\>200 ms, QRS\>110 ms, QTcF\<380 or \>450 ms, lead II T wave abnormalities. Non-specific T wave abnormalities in leads other than lead II are permissible if not accompanied by any other morphological abnormalities.
* Patients with infection e.g. dental abscess

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: To evaluate the safety, tolerability, efficacy and dose response of single oral doses of SAF312 in patients with postoperative dental pain
timeFrame: 24 hours
Secondary outcomes:
measure: To assess the pharmacokinetics of the single oral doses of SAF312 and Ibuprofen in patients with postoperative dental pain
timeFrame: 24 hours
measure: To measure: time-specific pain relief (PR), Total pain relief (TOTPAR), time to onset of analgesia, time to rescue medication
timeFrame: 24 hours
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Jean Brown Research
state: Utah
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: